July 12, 2022 Philips SmartSpeed AI-based software receives FDA 510(k) clearance, delivering breakthrough high-speed, high-resolution MR imaging Unique broad compatibility (97% of clinical protocols) allows faster and high-quality scans for virtually all patients with various conditions including those with implants Intelligent MR acceleration software helps drive increased MR department efficiency […]
Author: Ken Dropiewski
Canon Medical Systems USA Inc. Announces Expansion of Distributorship with the Acquisition of NXC Imaging
Tustin, California, July 11, 2022 (GLOBE NEWSWIRE) — Canon Medical Systems USA Inc., a commercial subsidiary of Canon Medical Systems Corporation and a global leader in innovative diagnostic imaging technology, today announces it has signed a definitive agreement to acquire NXC Imaging, a medical imaging equipment distributor and service provider […]
New Access Vascular Retrospective Data Review Demonstrates Midline Catheters Composed of Advanced Biomaterials May Improve Dwell Times
Data also finds using materials that mimic the body’s chemistry leads to meaningful reductions in complications such as phlebitis, occlusion, and infections BILLERICA, Mass., July 12, 2022 (GLOBE NEWSWIRE) — Access Vascular, Inc. (AVI) today shared initial findings from a retrospective review of patient records that demonstrates an increase in dwell times […]
Nuwellis Initiates Its Outpatient Heart Failure Strategy Using Aquadex Ultrafiltration Therapy
MINNEAPOLIS, July 12, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on improving the quality of life for people with fluid overload, today announced key takeaways from its recent physician-led webinar discussing the benefits of treating fluid overloaded heart failure (HF) patients with Aquadex® ultrafiltration (UF) in the […]
scPharmaceuticals Inc. Announces Positive Results from the AT HOME-HF Phase 2 Pilot Study in Heart Failure
Study results favor FUROSCIX® versus “treatment as usual” in composite primary endpoint and all secondary endpoints FUROSCIX demonstrated an acceptable tolerability profile Company on track for Q4 2022 commercial launch of FUROSCIX, if approved BURLINGTON, Mass., July 12, 2022 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on […]
FDA Clears Eko’s Heart Disease Detection AI for Adults and Pediatrics
First and only machine learning algorithm to assist healthcare professionals in identifying structural heart murmurs using a smart stethoscope OAKLAND, Calif., July 12, 2022 /PRNewswire/ — Eko, a digital health company advancing heart and lung disease detection, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Eko Murmur Analysis […]
CVRx Launches a new Barostim™ Programmer
The new Barostim Programmer launches in the U.S., making Barostim therapy programming simpler and enabling remote view access to enhance customer support MINNEAPOLIS, July 12, 2022 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure, has launched […]
Verve Therapeutics Doses First Human with an Investigational In Vivo Base Editing Medicine, VERVE-101, as a Potential Treatment for Heterozygous Familial Hypercholesterolemia
Phase 1b Clinical Trial, heart-1, Now Underway and Enrolling Patients with Heterozygous Familial Hypercholesterolemia in New Zealand Company Executing VERVE-101 Global Regulatory Strategy with Potential Clearances for a UK Clinical Trial Application and US Investigational New Drug Application in Second Half of 2022 CAMBRIDGE, Mass., July 12, 2022 (GLOBE NEWSWIRE) […]
Rexlemestrocel-L to be Highlighted at Maxim’s Panel on Late-Stage Advancements in Heart Failure Therapeutics and Management
NEW YORK, July 11, 2022 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that rexlemestrocel-L, its allogeneic “off-the-shelf” product candidate for the treatment of chronic heart failure (CHF) with reduced ejection fraction (HFrEF), will be highlighted in a panel discussion […]
Story Health Appoints Cardiovascular Changemaker Andrew Sauer, MD to Advisory Board
Renowned Cardiologist and Innovator Brings Unparalleled Expertise to Story Health and Fuels Mission of Transforming Care for Americans with Heart Failure SAN JOSE, Calif.–(BUSINESS WIRE)–Story Health, a health technology and services company that extends specialty care to patients’ homes, today announced the appointment of Dr. Andrew Sauer to its Board […]



